A Critical Review of the Antipsychotic Effects of Cannabidiol: 30 Years of a Translational Investigation
Antônio Waldo Zuardi(Universidade de São Paulo), Francisco Silveira Guimarães(Universidade de São Paulo), Zerrin Atakan(University of London), Philip McGuire(Oxford Health NHS Foundation Trust), Jaime E. C. Hallak(Conselho Nacional de Desenvolvimento Científico e Tecnológico), Sagnik Bhattacharyya(University of London), José Alexandre S. Crippa(Conselho Nacional de Desenvolvimento Científico e Tecnológico), Rocío Martín‐Santos(Conselho Nacional de Desenvolvimento Científico e Tecnológico)
Cited by 222
Related Papers
Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial
|Psychological Medicine|2018|819
Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients
|Neuropsychopharmacology|2011|763
Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment
|Molecular Psychiatry|2023|684
Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report
|Journal of Psychopharmacology|2010|530
Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report
|Brazilian Journal of Psychiatry|2015|484